It exhibits fungistatic, not fungicidal, activity against most susceptible species.

Diflucan can lead to clinically significant interactions with immunosuppressants like tacrolimus.

A cornerstone of antifungal therapy in resource-limited settings due to cost and availability.

Diflucan lacks activity against Histoplasma in the CNS, unlike itraconazole.

Activity against Coccidioides immitis makes it useful for certain non-meningeal forms of valley fever.

Diflucan is excreted in human milk, requiring careful risk-benefit analysis during lactation.

Diflucan can increase sulfonylurea levels, increasing hypoglycemia risk.

Diflucan is not effective for primary treatment of fungal brain abscesses.

Resistance to Diflucan is a growing concern, particularly with Candida glabrata and krusei.

Rifampin induces fluconazole metabolism, potentially leading to subtherapeutic levels.